Monthly Archives: February, 2018
Press Releases
New Late-Breaking XARELTO® (rivaroxaban) and INVOKANA® (canagliflozin) Data to be Presented at the American College of Cardiology’s Annual Scientific Session
New studies and late-breaking analyses from the Janssen Pharmaceutical Companies of Johnson & Johnson are among the 11 company abstracts accepted for presentation at...
News
CEGA creates new role to meet rising demand for private repatriation
CEGA, the repatriation, medical assistance and claims provider, has appointed a new business development manager to meet the rising demand for private medical repatriations...
Press Releases
Cega creates new role to meet rising demand for private repatriation
CEGA, the repatriation, medical assistance and claims provider, has appointed a new business development manager to meet the rising demand for private medical repatriations...
News
International Hospital Federation Awards entry submissions now open
Entry submissions for the 2018 International Hospital Federation (IHF) Awards is now open. Hospitals and healthcare organizations that have innovations,outstanding achievements and best practices...
Press Releases
ACG keen to Improve Technology for Authentication and Traceability of Capsules for the Pharmaceutical and Nutraceutical Industry: Signs Letter of Intent with Applied DNA...
Molecular labeling of capsules is intended to prevent counterfeiting The Letter of Intent between Applied DNA Sciences, Inc. and ACG grants ACG the rights...
News
Omega Healthcare among top 2 in ‘Market Impact’ and ‘Vision & Capability’, in the global Healthcare BPO Service Provider Market Assessment
Outperforming many well-entrenched businesses with its wide-ranging capabilities and diversified business footprint, Omega Healthcare breaks new ground in this critical study.
The detailed analysis of...
Press Releases
An additional FDA approval for Lilly’s Verzenio™ (abemaciclib), initial treatment for advanced breast cancer
Eli Lilly and Company announced that the U.S. FDA has approved VerzenioTM (abemaciclib) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
